OncoMatch/Clinical Trials/NCT07311408
SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure
Is NCT07311408 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including SHR-1701+Rivoceranib + SHR-2554 and SHR-1701 + Rivoceranib for gastric cancer (gc).
Treatment: SHR-1701+Rivoceranib + SHR-2554 · SHR-1701 + Rivoceranib — To investigate the efficacy of SHR-1701 combined with Rivoceranib, with or without SHR-2554, in patients with gastric or gastroesophageal junction adenocarcinoma who have progressed on or were intolerant to first-line immunotherapy-containing treatment
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Gastric Cancer
Esophageal Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Required: HER2 (ERBB2) negative expression (negative)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: checkpoint inhibitor
Disease progression on or intolerance to a prior treatment regimen that contained an immune checkpoint inhibitor (ICI)
Cannot have received: investigational agent
Treatment with any other investigational agent within 4 weeks prior to the first dose of the study drug, or within 5 half-lives of the previous investigational agent (whichever is longer)
Cannot have received: antitumor therapy
Any antitumor therapy (including radiotherapy, chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biotherapy, or tumor embolization) within 2 weeks prior to the first dose of the study drug
Cannot have received: anti-tumor vaccine
Prior administration of an anti-tumor vaccine or live vaccine within 4 weeks prior to the first dose
Lab requirements
Blood counts
Hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); ANC ≥ 1.5 × 10^9/L; Platelet count ≥ 90 × 10^9/L
Kidney function
Serum creatinine ≤ 1.5 × ULN
Liver function
Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50%; QTc interval < 450 ms for males and < 470 ms for females
Adequate organ and bone marrow function, defined as: Hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); ANC ≥ 1.5 × 10^9/L; Platelet count ≥ 90 × 10^9/L; Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN; Serum creatinine ≤ 1.5 × ULN; Left ventricular ejection fraction (LVEF) ≥ 50%; QTc interval < 450 ms for males and < 470 ms for females.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07311408 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent, antitumor therapy, anti-tumor vaccine disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 negative expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify